CA2061520C - Delivery system for enhanced onset and increased potency - Google Patents
Delivery system for enhanced onset and increased potency Download PDFInfo
- Publication number
- CA2061520C CA2061520C CA002061520A CA2061520A CA2061520C CA 2061520 C CA2061520 C CA 2061520C CA 002061520 A CA002061520 A CA 002061520A CA 2061520 A CA2061520 A CA 2061520A CA 2061520 C CA2061520 C CA 2061520C
- Authority
- CA
- Canada
- Prior art keywords
- tablet
- chosen
- salt
- mixtures
- citric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Abstract
The invention discloses a swallow tablet which is capable of disintegrating within less than about fifteen minutes and providing fast delivery of therapeutic drugs. The delivery system is composed of between 0.250 and 1.0 Gm of an alkali metal or alkaline-earth metal salt of an edible organic acid. A preferred delivery system is trisodium citrate.
Description
DELIVERY SYSTEM FOR ENHANCED ONSET
AND INCREASED POTENCY
Field of the Invention The invention relates to a delivery system for therapeutic drugs which may be incorporated into a solid dosage form to provide a swallowable tablet.
Specifically the invention relates to the use of salts of edible organic acids in combination with a therapeutic drug.
Backqround of the Invention Previously it has been shown that effervescent dosage forms may provide faster action for some drugs. This was often attributed to the fact that such dosage forms were dissolved in water prior to ingestion and therefor_ the drug was in solution and readily available for absorption.
However, the effervescent delivery system has been unsatisfactory for some consumers; and can present formulators with difficult taste masking problems.
It has now been found that the fast delivery of an effervescent system, with an enhanced onset of MS #1661 action, may be provided in a solid oral dosage form as a swallowable tablet.
Description of the Drawings The Figures relate to Example 1 where ranitidine was administered to dogs with a delivery system composed of trisodi.um citrate and bicarbonate.
Figure 1 is a graph of the reduction in tritratable acidity (percent) versus time after dosing (minutes) comparing the activity of the solid dosage form ("DRY") and an effervescent dosage ("WET") of the same concentration (0.3 mg/kg) and the same acid neutralizing capacity of 16 milliequivalents (mEq). The squares show the control dosage (i.e.
without antacid).
Figure 2 is a graph of the gastric acidity (pH) versus time after dosing (minutes) comparing the activity of the solid dosage form ("DRY") and an effervescent dosage ("WET") of the same concentration (0.3 mg/kg) and the same acid neutralizing capacity of 16 milliequ.ivalents. The squares show the control dosage (i.e. without antacid) and the triangles show the administration of water.
Figure 3 is a graph of the gastric acidity (pH) versus time after dosing (minutes) of the solid dosage form ("DRY") showing the effect on dogs.
MS #1661 ;r', ~ r~. ;,' c s k c;~ of 't~ .z.. i~.~ : !
Figure ~ is a graph of the reduction in tritratable acidity (percent) versus time after dosing (minutes) of the solid dosage form ("DRY") showing the effect on dogs.
Summary of the Invention The invention provides a delivery system for enhanced onset and increased potency o.f therapeutic drugs, The delivery system plus therapeutic may be provided in a solid oral dosage form, such as a swallow tablet. The delivery system comprises an effective amount of_ therapeutic drug and salt of an edible organic acid, wherein the salt is present in an amount of between 0.250 Gm and 1.0 Gm per tablet with at least about 0.5 Gm salt per dose. The edible organic acid is chosen from the group consisting of citric, malic, fumaric, tartaric and succinic acid or mixtures thereof. The salt is an alkali metal salt or an alkaline-earth metal salt or mixtures thereof.
Therapeutic drugs of. particular interest are chosen from the group consisting of analgesics, HZ Blockers and sympathomimetic amine drugs. The delivery system is preferably composed of trisodium citrate and may additionally contain a carbonate or bicarbonate.
Description of the Invention The invention provides a solid oral dosage form which may be swallowed. The tablet will disintegrate in vivo within about fifteen minutes and provide enhanced onset of action over previous solid oral MS #1661 h,l i~
dosage forms on the order of the enhanced onset seen with the effervescent delivery system. It is specu-lated, though not relied on, that the delivery system disclosed herein provides rapid stomach emptying on the order of that seen previously only with effer-vescent systems which are dissolved and ingested as liquids. This rapid stomach emptying gets the active drug to the site of absorption faster than previous solid dosage forms and therefore provides for a more rapid onset of action and increased potency.
The delivery system is composed of a salt of an edible organic acid in an amount of at least about 0.5 Gm per dose. Practical limits on tablet size means that a tablet could contain materials up to a total of about 1.5 Gm, which must include the salt, active drug and all other materials required for tabletting. A one tablet dose would contain from about 0.5 GM to about 1.0 Gm acid salt. If two tablets are to provide a dose, a single tablet could contain from about 0.25 Gm to about 1.0 Gm.
~dibAe organic acids useful in the invention are citric acid, malic acid, fumaric acid, tartaric acid, succinic acid and the like or mixtures 'thereof. Most preferred is citric acid. Useful salts include the 2.5 alkali metal salts and alkali-earth metal salts of these acids such as sodium, potassium, calcium or magnesium or mixtures thereof. A preferred salt is trisodium citrate.
MS #1661 ._5_ The composition may also contain a carbonate or bicarbonate to facilitate disintegration, or other such disintegrants. In addition, other excipients, useful in the art of tabletting, such as lubricants, binders, buffers, antioxidants, and colorants may be used. The tablet may be coated with a thin layer of a protective coating to provide a dustless and easily swallowed dosage form which is well known to those of skill in the art.
In addition to the delivery system and excipients, the solid dosage form would contain an effective amount of an active drug substance. This amount may be the therapeutically effective amount commonly used in prescription dosage forms, or may, because of the efficacy of the delivery system provided herein, be a reduced amount. Preferred therapeutics include those from the classes of analgesics, Ha Blockers and sympathomimetic amine drugs (commonly referred to as decongestants).
In particular, the dosage form is useful with analgesic, chosen from the group consisting of aspirin, acetaminophen, ibuprofen and ketoprofen; HZ
Blockers chosen from the group consisting of raniti-dine, famotidine, cimetidine and nizatidine; and the sympathomimetic amine drugs chosen from the graup consisting of phenylpropanolamine, phenylephrine and pseudoephridine. Because of the ability of this delivery system to provide enhanced onset and increased potency (synergy), a lower dose than that used with a prescription dosage in the traditional tablet forms M~u #1661 E;, , ,.., r' r.
-6" ~, _~ a,~ .' .' ;~ ~.i presently available, may be used. Therefore, this swallow oral dosage form will be particularly useful for over-the-counter medications.
The composition may be provided as a capsule, tablet or caplet or other solid oral dosage form.
A preferred method of preparing the granulate for the oral dosage form may be used generally to prepare granulates of sodium salts of acidic thera-peutic drugs of limited water solubility. The acidic therapeutic drug of interest is mixed with anhydrous trisodium citrate to form a dry mixture; to the dry mixture is added a near saturated aqueous solution of trisodium citrate to form an overwet granulation mixture. A near saturated solution of trisodium citrate is approximately 40 ~ by weight trisodium citrate. An overwet mixture is a mixture that is wetter than commonly used by those of skill in the art to prepare granulates. It may be termed "more than damp" and is wet enough for a chemical reaction to take place between the citrate and the drug. An overwet mixture may be described as doughy or may even approach a paste-like consistency. The overwet granulation mixture is then mixed for a time sufficient to allow the anhydrous trisadium citrate to hydrate, forming a mixture dry enough to granulate. The hydrated mixture is then granulated as is standard to the art.
The following examples disclose preferred embodiments of the invention, but do not limit the 1~5 #1661 l ,. ," ~; .~ ~
applicability of the invention which is solely defined by the claims.
EXAMPLES
Example 1 - Ftanitidine This study was designed to test the activity of a dry formulation of Effervescent Antacid Base (EAB, described below) plus ranitidine combination and to compare its effectiveness with 'that of the previously tested wet formulations (those dissolved in water prior to ingestion}. The combination of 0.3 mg/kg ranitidine + 16 mEq EAB was selected for testing.
Studies monitored gastric secretion in gastric fistula beagle dogs. Beagle dogs were dosed with two capsules containing (in total} 1.273 mg trisodium citrate (2 HBO), 575 mg heat treated sodium bicarbonate plus 0.3 mg/kg of the H2 Blocker ranitidine (as per individual weight of each Beagle). This dosage of ranitidine (administered without the effervescent antacid base or sodium citrate) had been shown previously to be ineffective as an anti-secretory agent for such dogs. Altogether 8 trials (8 dogs) were performed. In previous trials with "WET" dosage forms, ranitidine with the effervescent antacid base was dissolved and administered to dogs via gastric fistula. In these trials, the test .formulation was not dissolved in water and was not administered as a solution via the gastric fistula. Instead, for each dog, the appropriate amounts of dry ingredients were MS #1661 ~
.~ d'° .~ : °.' -' ~ s mixed and divided into two capsules. The capsules were given orally to the dogs and washed down by placing small amcunts of water on tongue via a syringe filled with 28 mla. About half the syringe content was used for washing down; content remaining was administered to dog via fistula. Thus, amounts of all constituents including water, were the same as used in previous tests.
Results show that the effect of the two dosage forms is practically identical. A comparison of the effects of the two formulations on tritratable acidity are presented in Figure 1, and a comparison o.f the effects on pI-i are presented in Figure 2.
Inspection of these figures reveals that results of the present test with dry formulation, almost exactly duplicate the results o.f the previous tests with wet formulation. Within the limits of these tests, no significant differences between the two formulations can be discerned.
Because 2 of the 8 dogs tested received closed capsules instead of open capsules, and because 3 of the dogs tested experienced vomiting during the test, the influence of these variables needed to be examined.
Thus, the means for all dogs were compared to the means for only thase dogs which received closed capsules (Figure 3), and were compared to the means for only those dogs which did not vomit (Figure 4).
These comparisons reveal that, regardless of the variables of capsule closure or vomiting, the apparent MS #1661 equivalency of the two dosage forms remains definitely established.
The results showed that the ranitidine with the delivery system of the invention was significantly 5 more effective than would be expected from a solid oral dosage form (See Figure 1-4). The figures demonstrate that a synergistic effect was produced when ranitidine, at an otherwise ineffective dose, combined with the delivery system utilized in these 10 experiments and administered in a solid oral dosage form.
Similar results were obtained when ranitidine was administered to Beagles with a sodium citrate delivery system (not including a carbonate or bicar-15 bonate).
Example 2 - Acetaminophen Swallow Tablet Formulation Formula 001 Total mg/tab Ingredients Quantities 20 361.11 Acetaminophen 90% (Compa~3' L) 108.33 Gm 648.11 Formula 169 (see below) 194.67 Gm 48.39 Sodium Starch Glycolate 14.52 Gm 0.10 Docusate Sodium, Sodium 0.03 Gm Benzoate ( 85 :,15 ) , 25 20.00 .; 6.00 Gm Crospovidone (Polyplasdone XL) 1:50 Magnesium Stearate 0.45 Gm 1080.00 324.00 Gm Pass all ingredients thru a #24 mesh screen to delump.
Trade-mark MS #1661 :~' g !e t, ~.~ ~. ;; !~ ti Add all together except 'the Magnesium Stearate and mix in a V-Blender for 7 minutes.
Add the Magnesium Stearate and blend for another 3 minutes.
Compress into tablets using 0.344" x 0.750" capsule shaped tooling.
Formula 169 Total ~ W/W Inqredients Quantities 7.0 Starch 1500 140 Gm 93.0 Trisodium Citrate 1860 Gm Dihydrate 100.0 2000 Gm Add powders 'to a 8 quart V-Blender with Intensifier Bar.
Dry mix with Intensifier Bar turned an for 3 minutes.
Wet granulate using 193 Gm of Water.
Discharge and pass thru a #24 mesh screen.
Dry in hoi~ air oven at 130 F. overnight, (ca. 16 hours ) .
Dry size by passing thru a #24 mesh screen.
MS #1661 Example 3 - Aspiriri~Swallow Tablet Formulation Total mq/tab Ingredients Quantities 362.0 Aspirin:':& Starch Granulation 72.4 Gm 90%
5 700.0 Formula 169 (See Example 2) 140.0 Gm 50.0 Sodium Starch Glycolate 10.0 Gm 20.0 Crospovidone (Polyplasdone XL) 4.0 Gm 60.0 Formula 038* 12.0 Gm 18.0 Formula 171* 3.6 Gm 10 1210.0 242.0 Gm Dry Sodium Starch Glycolate and Crospovidone in hot air oven at 130°F overnight, (ca. 16 hours).
Add all ingredients to a V-Blender and mix for ten minutes.
15 Compress into tablets using 0.344" x 0.750" capsule shaped tooling.
*Formula 038 Total % W/W Ingredients Quantities 20 6.0 Polyethylene Glycol 8000 30.0 Gm 94.0 Trisodium Citrate, Anhydrous 470.0 Gm Powder 100.0 500.0 Gm Blend powders together and then pass them thru a 4"
25 Air Mill (micronizer).
*Formula 171 Total % W/W Ingredients Quantities 0.2 Dioctyl Sodium 1.0 Gm 30 Sulfosuccinate (DOSS) 99.8 Calcium Sorbate 500.0 Gm 100.0 501.0 Gm 'I'rade-mark MS #1661 ' .,a ;
y ~r, L:r '~' ~~ .?. e.e :,a ~~
Prepare 200 Gm of 0.5$ w/w DOSS from Complemix-50 (50~ DOSS) by mixing together 2 Gm of Complemix-50 and 198 Gm of water.
Add the calcium sorbate to the pot of a Hobart Tabletop Mixer and add the 200 Gm of DOSS solution to it while mixing.
With continued mixing add an additional 135 Gm of water.
Discharge the dampened powder and dry it in a hot air oven at 130°F overnight, (ca. 16 hours).
Pass the dried powder thru a #60 mesh screen.
Example 4 - Ibuprofen Swallow Tablet Formulation Formula 182 Total mcL/tab,Ingredients Quantities 792.0 Formula 144* 158.4 Gm 60.0 Sodium Starch Glycolate 12.0 Gm 45.0 Formula 038 (see Example 9.0 Gm 3) 14.0 Formula 171 (see Example 2.8 Gm 3) 911.0 182.2 Gm Add all ingredients to a bottle, cap it, and mix the contents for 10 minutes using a Turbula Mixer.
Compress into tablets using 0.344" x 0.700" capsule shaped tooling.
MS #1661 ~ i~ ~ ~. ~.
*Formula 144 Pass a quantity of Ibuprofen thru a #24 mesh screen to delump it.
Prepare a powder mixture of 200.0 Gm of Ibuprofen and 400.0 Gm of Trisodium Citrate, anhydrous Powder by mixing them together in the pot of a Tabletop Hobart Mixer.
Prepare a 400 Gm quantity of 40~ w/w solution of Trisodium Citrate Dehydrate in Water by dissolving 160 Gm of it in 240 Gm of Water.
Hlith the Hobart Mixer running at slow speed, pour in 338 Gm of the 40~ solution all at once, on top of the Ibuprofen and Trisodium Citrate mixture.
Continue mixing for 20 minutes.
Discharge and pass thru a #24 mesh screen.
Dry in hat air over at 130°F overnight, (ca. 16 hours .
Dry size by passing thru a #24 mesh screen.
792 mg of the dried granulation provides 200 mg of Ibuprofen in water soluble form, and 592 mg of Trisodium Citrate Dehydrate.
M5 #1661 Example 5 - Ketoprofen Swallow Tablet Formulation Total mq/tab Ingredients Quantities 110.0 Formula 118* 22.0 Gm 5 700.0 Formula 169 (see Example 2) 140.0 Gm 60.0 Sodium Starc h Glycolate 12.0 Gm 20.0 Crospovidone (Polyplasdone XL) 4.0 Gm 45.0 Formula 038 (see Example 3) 9.0 Gm 14.0 Formula 171 (see Example 3) 2.8 Gm 10 949.0 189.8 Gm Add all ingredients to a bottle, cap it, and mix the contents for 10 minutes using a Turbula Mixer.
Compress into tablets using 0.344" x 0.700" capsule shaped tooling.
15 *Formula 118 Weight 2.0 Gm of Decaglycerol Tetraoleate (CaproY~ 10 G 4 0) into a 140 mL beaker. Add 98.0 Gm of water and mix with a Lighnin Mixer until all of the Caprol is dispersed.
20 Add 50.0 Gm of Ketoprofen and 150.0 Gm of Trisodium Citrate, Anhydrous Powder to a large mortar and pestle, and triturate until well mixed.
Add 85.2 Gm of the Caprol dispersion all at once to the powder mixture and triturate thoroughly, first 25 forming a sticky paste which begins to dry up in a few minutes.
Knead the soft mass with the hands, and when it begins to get crumbly, pass it thru a #24 mesh screen.
MS #1661 z'rade-mark Dry in hot air oven at 130°F overnight, (ca. 16 hours).
Dry size by passing thru a #24 mesh screen.
110 mg of the dried granulation provides 25 mg of 5 Ketoprofen in water soluble form, and ca. 85 mg of Trisodium Citrate Dihydrate.
Example 6 - Ranitidine Swallow Tablet Formulation Formula 188 Total 10 mq/tab Ingredients Quantities 140.0 Formula 181* 28.0 Gm 635.0 Formula 169 (see Example 2) 127.0 Gm 135.0 Starch 1500 27.0 Gm 5.0 Magnesium Stearate 1.0 Gm 15 5.0 Formula 171 (see Examplg 3) 1.0 Gm 5.0 Silicon Dioxide (Syloid'244FP) 1.0 Gm 925.0 185.0 Gm *Formula 181 Total 20 % W/W Ingredients Quantities 10.0 Ranitidine Hydrochloride 50.0 Gm 10.0 Calcium Acetate Powder 50.0 Gm (Trace) Mixed Tocopherols (Trace Amt.) 80.0 Mannitol Powder 400.0 Gm 25 100.0 500.0 Gm Prepare a 0.1% solution of Covi-Ox~T-30P (dried mixed tocopherol concentrate) ~n water.
Pass the powders thru a #24 mesh screen to delump.
Add them to the pot of a Hobart Tabletop Mixer, and 30 while mixing add 30 Gm of the Covi-Ox Solution.
MS #1661 ~~ Trade-mark _1~_ o r~ ;
~~.~ z;~~~~
Pass the wet granulate thru a #24 mesh screen and dry it in a hot air oven at 130°F overnight, (ca. 16 hours).
Dry size by passing thru a #24 mesh screen.
Example 7, - Pseudoephedrine Swallow Tablet Formulation Total m-q/tab Ingredients Quantities 20.0 Pseudoephedrine Hydrochloride4.0 Gm 800.0 Formula 169 (see Example 2) 160.0 Gm 240.0 Sodium Bicarbonate, Heat Treated Gm 48.0 75.0 Sodium Starch Glycolate 15.0 Gm 25.0 Grospovidone (Polyplasdone 5.0 Gm XL) 6.0 Magnesium Stearate 1.2 Gm 6.0 Formula 171 (see Example 3) 1.2 Gm 6.0 Silicon Dioxide (Syloid FP) 1.2 Gm 1178.0 235.6 Gm Pass all ingredients thru a #24 mesh screen to delump.
P.dd all ingredients to a bottle, cap it, and mix the 2U contents for 10 rninutes using a Turbula Mixer.
Compress into tablets using 0.344" x 0.750" capsule shaped tooling.
It should be understood that many modifications and variations can be made in the proportions and components used herein without departing from the spirit and scope of the invention, which is solely defined by the claims.
MS #1661
AND INCREASED POTENCY
Field of the Invention The invention relates to a delivery system for therapeutic drugs which may be incorporated into a solid dosage form to provide a swallowable tablet.
Specifically the invention relates to the use of salts of edible organic acids in combination with a therapeutic drug.
Backqround of the Invention Previously it has been shown that effervescent dosage forms may provide faster action for some drugs. This was often attributed to the fact that such dosage forms were dissolved in water prior to ingestion and therefor_ the drug was in solution and readily available for absorption.
However, the effervescent delivery system has been unsatisfactory for some consumers; and can present formulators with difficult taste masking problems.
It has now been found that the fast delivery of an effervescent system, with an enhanced onset of MS #1661 action, may be provided in a solid oral dosage form as a swallowable tablet.
Description of the Drawings The Figures relate to Example 1 where ranitidine was administered to dogs with a delivery system composed of trisodi.um citrate and bicarbonate.
Figure 1 is a graph of the reduction in tritratable acidity (percent) versus time after dosing (minutes) comparing the activity of the solid dosage form ("DRY") and an effervescent dosage ("WET") of the same concentration (0.3 mg/kg) and the same acid neutralizing capacity of 16 milliequivalents (mEq). The squares show the control dosage (i.e.
without antacid).
Figure 2 is a graph of the gastric acidity (pH) versus time after dosing (minutes) comparing the activity of the solid dosage form ("DRY") and an effervescent dosage ("WET") of the same concentration (0.3 mg/kg) and the same acid neutralizing capacity of 16 milliequ.ivalents. The squares show the control dosage (i.e. without antacid) and the triangles show the administration of water.
Figure 3 is a graph of the gastric acidity (pH) versus time after dosing (minutes) of the solid dosage form ("DRY") showing the effect on dogs.
MS #1661 ;r', ~ r~. ;,' c s k c;~ of 't~ .z.. i~.~ : !
Figure ~ is a graph of the reduction in tritratable acidity (percent) versus time after dosing (minutes) of the solid dosage form ("DRY") showing the effect on dogs.
Summary of the Invention The invention provides a delivery system for enhanced onset and increased potency o.f therapeutic drugs, The delivery system plus therapeutic may be provided in a solid oral dosage form, such as a swallow tablet. The delivery system comprises an effective amount of_ therapeutic drug and salt of an edible organic acid, wherein the salt is present in an amount of between 0.250 Gm and 1.0 Gm per tablet with at least about 0.5 Gm salt per dose. The edible organic acid is chosen from the group consisting of citric, malic, fumaric, tartaric and succinic acid or mixtures thereof. The salt is an alkali metal salt or an alkaline-earth metal salt or mixtures thereof.
Therapeutic drugs of. particular interest are chosen from the group consisting of analgesics, HZ Blockers and sympathomimetic amine drugs. The delivery system is preferably composed of trisodium citrate and may additionally contain a carbonate or bicarbonate.
Description of the Invention The invention provides a solid oral dosage form which may be swallowed. The tablet will disintegrate in vivo within about fifteen minutes and provide enhanced onset of action over previous solid oral MS #1661 h,l i~
dosage forms on the order of the enhanced onset seen with the effervescent delivery system. It is specu-lated, though not relied on, that the delivery system disclosed herein provides rapid stomach emptying on the order of that seen previously only with effer-vescent systems which are dissolved and ingested as liquids. This rapid stomach emptying gets the active drug to the site of absorption faster than previous solid dosage forms and therefore provides for a more rapid onset of action and increased potency.
The delivery system is composed of a salt of an edible organic acid in an amount of at least about 0.5 Gm per dose. Practical limits on tablet size means that a tablet could contain materials up to a total of about 1.5 Gm, which must include the salt, active drug and all other materials required for tabletting. A one tablet dose would contain from about 0.5 GM to about 1.0 Gm acid salt. If two tablets are to provide a dose, a single tablet could contain from about 0.25 Gm to about 1.0 Gm.
~dibAe organic acids useful in the invention are citric acid, malic acid, fumaric acid, tartaric acid, succinic acid and the like or mixtures 'thereof. Most preferred is citric acid. Useful salts include the 2.5 alkali metal salts and alkali-earth metal salts of these acids such as sodium, potassium, calcium or magnesium or mixtures thereof. A preferred salt is trisodium citrate.
MS #1661 ._5_ The composition may also contain a carbonate or bicarbonate to facilitate disintegration, or other such disintegrants. In addition, other excipients, useful in the art of tabletting, such as lubricants, binders, buffers, antioxidants, and colorants may be used. The tablet may be coated with a thin layer of a protective coating to provide a dustless and easily swallowed dosage form which is well known to those of skill in the art.
In addition to the delivery system and excipients, the solid dosage form would contain an effective amount of an active drug substance. This amount may be the therapeutically effective amount commonly used in prescription dosage forms, or may, because of the efficacy of the delivery system provided herein, be a reduced amount. Preferred therapeutics include those from the classes of analgesics, Ha Blockers and sympathomimetic amine drugs (commonly referred to as decongestants).
In particular, the dosage form is useful with analgesic, chosen from the group consisting of aspirin, acetaminophen, ibuprofen and ketoprofen; HZ
Blockers chosen from the group consisting of raniti-dine, famotidine, cimetidine and nizatidine; and the sympathomimetic amine drugs chosen from the graup consisting of phenylpropanolamine, phenylephrine and pseudoephridine. Because of the ability of this delivery system to provide enhanced onset and increased potency (synergy), a lower dose than that used with a prescription dosage in the traditional tablet forms M~u #1661 E;, , ,.., r' r.
-6" ~, _~ a,~ .' .' ;~ ~.i presently available, may be used. Therefore, this swallow oral dosage form will be particularly useful for over-the-counter medications.
The composition may be provided as a capsule, tablet or caplet or other solid oral dosage form.
A preferred method of preparing the granulate for the oral dosage form may be used generally to prepare granulates of sodium salts of acidic thera-peutic drugs of limited water solubility. The acidic therapeutic drug of interest is mixed with anhydrous trisodium citrate to form a dry mixture; to the dry mixture is added a near saturated aqueous solution of trisodium citrate to form an overwet granulation mixture. A near saturated solution of trisodium citrate is approximately 40 ~ by weight trisodium citrate. An overwet mixture is a mixture that is wetter than commonly used by those of skill in the art to prepare granulates. It may be termed "more than damp" and is wet enough for a chemical reaction to take place between the citrate and the drug. An overwet mixture may be described as doughy or may even approach a paste-like consistency. The overwet granulation mixture is then mixed for a time sufficient to allow the anhydrous trisadium citrate to hydrate, forming a mixture dry enough to granulate. The hydrated mixture is then granulated as is standard to the art.
The following examples disclose preferred embodiments of the invention, but do not limit the 1~5 #1661 l ,. ," ~; .~ ~
applicability of the invention which is solely defined by the claims.
EXAMPLES
Example 1 - Ftanitidine This study was designed to test the activity of a dry formulation of Effervescent Antacid Base (EAB, described below) plus ranitidine combination and to compare its effectiveness with 'that of the previously tested wet formulations (those dissolved in water prior to ingestion}. The combination of 0.3 mg/kg ranitidine + 16 mEq EAB was selected for testing.
Studies monitored gastric secretion in gastric fistula beagle dogs. Beagle dogs were dosed with two capsules containing (in total} 1.273 mg trisodium citrate (2 HBO), 575 mg heat treated sodium bicarbonate plus 0.3 mg/kg of the H2 Blocker ranitidine (as per individual weight of each Beagle). This dosage of ranitidine (administered without the effervescent antacid base or sodium citrate) had been shown previously to be ineffective as an anti-secretory agent for such dogs. Altogether 8 trials (8 dogs) were performed. In previous trials with "WET" dosage forms, ranitidine with the effervescent antacid base was dissolved and administered to dogs via gastric fistula. In these trials, the test .formulation was not dissolved in water and was not administered as a solution via the gastric fistula. Instead, for each dog, the appropriate amounts of dry ingredients were MS #1661 ~
.~ d'° .~ : °.' -' ~ s mixed and divided into two capsules. The capsules were given orally to the dogs and washed down by placing small amcunts of water on tongue via a syringe filled with 28 mla. About half the syringe content was used for washing down; content remaining was administered to dog via fistula. Thus, amounts of all constituents including water, were the same as used in previous tests.
Results show that the effect of the two dosage forms is practically identical. A comparison of the effects of the two formulations on tritratable acidity are presented in Figure 1, and a comparison o.f the effects on pI-i are presented in Figure 2.
Inspection of these figures reveals that results of the present test with dry formulation, almost exactly duplicate the results o.f the previous tests with wet formulation. Within the limits of these tests, no significant differences between the two formulations can be discerned.
Because 2 of the 8 dogs tested received closed capsules instead of open capsules, and because 3 of the dogs tested experienced vomiting during the test, the influence of these variables needed to be examined.
Thus, the means for all dogs were compared to the means for only thase dogs which received closed capsules (Figure 3), and were compared to the means for only those dogs which did not vomit (Figure 4).
These comparisons reveal that, regardless of the variables of capsule closure or vomiting, the apparent MS #1661 equivalency of the two dosage forms remains definitely established.
The results showed that the ranitidine with the delivery system of the invention was significantly 5 more effective than would be expected from a solid oral dosage form (See Figure 1-4). The figures demonstrate that a synergistic effect was produced when ranitidine, at an otherwise ineffective dose, combined with the delivery system utilized in these 10 experiments and administered in a solid oral dosage form.
Similar results were obtained when ranitidine was administered to Beagles with a sodium citrate delivery system (not including a carbonate or bicar-15 bonate).
Example 2 - Acetaminophen Swallow Tablet Formulation Formula 001 Total mg/tab Ingredients Quantities 20 361.11 Acetaminophen 90% (Compa~3' L) 108.33 Gm 648.11 Formula 169 (see below) 194.67 Gm 48.39 Sodium Starch Glycolate 14.52 Gm 0.10 Docusate Sodium, Sodium 0.03 Gm Benzoate ( 85 :,15 ) , 25 20.00 .; 6.00 Gm Crospovidone (Polyplasdone XL) 1:50 Magnesium Stearate 0.45 Gm 1080.00 324.00 Gm Pass all ingredients thru a #24 mesh screen to delump.
Trade-mark MS #1661 :~' g !e t, ~.~ ~. ;; !~ ti Add all together except 'the Magnesium Stearate and mix in a V-Blender for 7 minutes.
Add the Magnesium Stearate and blend for another 3 minutes.
Compress into tablets using 0.344" x 0.750" capsule shaped tooling.
Formula 169 Total ~ W/W Inqredients Quantities 7.0 Starch 1500 140 Gm 93.0 Trisodium Citrate 1860 Gm Dihydrate 100.0 2000 Gm Add powders 'to a 8 quart V-Blender with Intensifier Bar.
Dry mix with Intensifier Bar turned an for 3 minutes.
Wet granulate using 193 Gm of Water.
Discharge and pass thru a #24 mesh screen.
Dry in hoi~ air oven at 130 F. overnight, (ca. 16 hours ) .
Dry size by passing thru a #24 mesh screen.
MS #1661 Example 3 - Aspiriri~Swallow Tablet Formulation Total mq/tab Ingredients Quantities 362.0 Aspirin:':& Starch Granulation 72.4 Gm 90%
5 700.0 Formula 169 (See Example 2) 140.0 Gm 50.0 Sodium Starch Glycolate 10.0 Gm 20.0 Crospovidone (Polyplasdone XL) 4.0 Gm 60.0 Formula 038* 12.0 Gm 18.0 Formula 171* 3.6 Gm 10 1210.0 242.0 Gm Dry Sodium Starch Glycolate and Crospovidone in hot air oven at 130°F overnight, (ca. 16 hours).
Add all ingredients to a V-Blender and mix for ten minutes.
15 Compress into tablets using 0.344" x 0.750" capsule shaped tooling.
*Formula 038 Total % W/W Ingredients Quantities 20 6.0 Polyethylene Glycol 8000 30.0 Gm 94.0 Trisodium Citrate, Anhydrous 470.0 Gm Powder 100.0 500.0 Gm Blend powders together and then pass them thru a 4"
25 Air Mill (micronizer).
*Formula 171 Total % W/W Ingredients Quantities 0.2 Dioctyl Sodium 1.0 Gm 30 Sulfosuccinate (DOSS) 99.8 Calcium Sorbate 500.0 Gm 100.0 501.0 Gm 'I'rade-mark MS #1661 ' .,a ;
y ~r, L:r '~' ~~ .?. e.e :,a ~~
Prepare 200 Gm of 0.5$ w/w DOSS from Complemix-50 (50~ DOSS) by mixing together 2 Gm of Complemix-50 and 198 Gm of water.
Add the calcium sorbate to the pot of a Hobart Tabletop Mixer and add the 200 Gm of DOSS solution to it while mixing.
With continued mixing add an additional 135 Gm of water.
Discharge the dampened powder and dry it in a hot air oven at 130°F overnight, (ca. 16 hours).
Pass the dried powder thru a #60 mesh screen.
Example 4 - Ibuprofen Swallow Tablet Formulation Formula 182 Total mcL/tab,Ingredients Quantities 792.0 Formula 144* 158.4 Gm 60.0 Sodium Starch Glycolate 12.0 Gm 45.0 Formula 038 (see Example 9.0 Gm 3) 14.0 Formula 171 (see Example 2.8 Gm 3) 911.0 182.2 Gm Add all ingredients to a bottle, cap it, and mix the contents for 10 minutes using a Turbula Mixer.
Compress into tablets using 0.344" x 0.700" capsule shaped tooling.
MS #1661 ~ i~ ~ ~. ~.
*Formula 144 Pass a quantity of Ibuprofen thru a #24 mesh screen to delump it.
Prepare a powder mixture of 200.0 Gm of Ibuprofen and 400.0 Gm of Trisodium Citrate, anhydrous Powder by mixing them together in the pot of a Tabletop Hobart Mixer.
Prepare a 400 Gm quantity of 40~ w/w solution of Trisodium Citrate Dehydrate in Water by dissolving 160 Gm of it in 240 Gm of Water.
Hlith the Hobart Mixer running at slow speed, pour in 338 Gm of the 40~ solution all at once, on top of the Ibuprofen and Trisodium Citrate mixture.
Continue mixing for 20 minutes.
Discharge and pass thru a #24 mesh screen.
Dry in hat air over at 130°F overnight, (ca. 16 hours .
Dry size by passing thru a #24 mesh screen.
792 mg of the dried granulation provides 200 mg of Ibuprofen in water soluble form, and 592 mg of Trisodium Citrate Dehydrate.
M5 #1661 Example 5 - Ketoprofen Swallow Tablet Formulation Total mq/tab Ingredients Quantities 110.0 Formula 118* 22.0 Gm 5 700.0 Formula 169 (see Example 2) 140.0 Gm 60.0 Sodium Starc h Glycolate 12.0 Gm 20.0 Crospovidone (Polyplasdone XL) 4.0 Gm 45.0 Formula 038 (see Example 3) 9.0 Gm 14.0 Formula 171 (see Example 3) 2.8 Gm 10 949.0 189.8 Gm Add all ingredients to a bottle, cap it, and mix the contents for 10 minutes using a Turbula Mixer.
Compress into tablets using 0.344" x 0.700" capsule shaped tooling.
15 *Formula 118 Weight 2.0 Gm of Decaglycerol Tetraoleate (CaproY~ 10 G 4 0) into a 140 mL beaker. Add 98.0 Gm of water and mix with a Lighnin Mixer until all of the Caprol is dispersed.
20 Add 50.0 Gm of Ketoprofen and 150.0 Gm of Trisodium Citrate, Anhydrous Powder to a large mortar and pestle, and triturate until well mixed.
Add 85.2 Gm of the Caprol dispersion all at once to the powder mixture and triturate thoroughly, first 25 forming a sticky paste which begins to dry up in a few minutes.
Knead the soft mass with the hands, and when it begins to get crumbly, pass it thru a #24 mesh screen.
MS #1661 z'rade-mark Dry in hot air oven at 130°F overnight, (ca. 16 hours).
Dry size by passing thru a #24 mesh screen.
110 mg of the dried granulation provides 25 mg of 5 Ketoprofen in water soluble form, and ca. 85 mg of Trisodium Citrate Dihydrate.
Example 6 - Ranitidine Swallow Tablet Formulation Formula 188 Total 10 mq/tab Ingredients Quantities 140.0 Formula 181* 28.0 Gm 635.0 Formula 169 (see Example 2) 127.0 Gm 135.0 Starch 1500 27.0 Gm 5.0 Magnesium Stearate 1.0 Gm 15 5.0 Formula 171 (see Examplg 3) 1.0 Gm 5.0 Silicon Dioxide (Syloid'244FP) 1.0 Gm 925.0 185.0 Gm *Formula 181 Total 20 % W/W Ingredients Quantities 10.0 Ranitidine Hydrochloride 50.0 Gm 10.0 Calcium Acetate Powder 50.0 Gm (Trace) Mixed Tocopherols (Trace Amt.) 80.0 Mannitol Powder 400.0 Gm 25 100.0 500.0 Gm Prepare a 0.1% solution of Covi-Ox~T-30P (dried mixed tocopherol concentrate) ~n water.
Pass the powders thru a #24 mesh screen to delump.
Add them to the pot of a Hobart Tabletop Mixer, and 30 while mixing add 30 Gm of the Covi-Ox Solution.
MS #1661 ~~ Trade-mark _1~_ o r~ ;
~~.~ z;~~~~
Pass the wet granulate thru a #24 mesh screen and dry it in a hot air oven at 130°F overnight, (ca. 16 hours).
Dry size by passing thru a #24 mesh screen.
Example 7, - Pseudoephedrine Swallow Tablet Formulation Total m-q/tab Ingredients Quantities 20.0 Pseudoephedrine Hydrochloride4.0 Gm 800.0 Formula 169 (see Example 2) 160.0 Gm 240.0 Sodium Bicarbonate, Heat Treated Gm 48.0 75.0 Sodium Starch Glycolate 15.0 Gm 25.0 Grospovidone (Polyplasdone 5.0 Gm XL) 6.0 Magnesium Stearate 1.2 Gm 6.0 Formula 171 (see Example 3) 1.2 Gm 6.0 Silicon Dioxide (Syloid FP) 1.2 Gm 1178.0 235.6 Gm Pass all ingredients thru a #24 mesh screen to delump.
P.dd all ingredients to a bottle, cap it, and mix the 2U contents for 10 rninutes using a Turbula Mixer.
Compress into tablets using 0.344" x 0.750" capsule shaped tooling.
It should be understood that many modifications and variations can be made in the proportions and components used herein without departing from the spirit and scope of the invention, which is solely defined by the claims.
MS #1661
Claims (19)
1. A tablet comprising an effective amount of a therapeutic drug and an alkali metal or alkaline earth metal salt of an edible organic acid, wherein the salt is present in an amount of between 0.250 Gm and 1.0 Gm per tablet and the edible organic acid is chosen from the group consisting of citric, malic, fumaric, tartaric and succinic acid or mixtures thereof.
2. The tablet of claim 1 wherein the edible organic acid salt is an alkali metal salt or an alkaline-earth metal salt or mixtures thereof.
3. The tablet of claim 1 which additionally comprises a carbonate or bicarbonate.
4. The tablet of claim 1 wherein the therapeutic drug is chosen from the group consisting of analgesics, H2 Blockers and sympathonimetic amine drugs.
5. A tablet, comprising:
(a) an effective amount of a therapeutic drug chosen from the group consisting of analgesics, H2 Blockers and sympathomimetic amine drugs; and (b) between about 0.250 Gm and 1.0 Gm per tablet of an alkali metal or alkaline-earth metal salt of an edible organic acid chosen from the group consisting of citric, malic, fumaric, tartaric and succinic acid.
(a) an effective amount of a therapeutic drug chosen from the group consisting of analgesics, H2 Blockers and sympathomimetic amine drugs; and (b) between about 0.250 Gm and 1.0 Gm per tablet of an alkali metal or alkaline-earth metal salt of an edible organic acid chosen from the group consisting of citric, malic, fumaric, tartaric and succinic acid.
6. The tablet of claim 5 which additionally comprises a carbonate or bicarbonate.
7. A tablet, comprising:
(a) an effective amount of an H2 Blocker chosen from the group consisting of ranitidine, cimetidine, nizatidine or famotidine; and (b) from about 0.250 to about 1.0 Gm of an alkali metal or alkaline-earth metal salts of citric acid or mixtures of such salts.
(a) an effective amount of an H2 Blocker chosen from the group consisting of ranitidine, cimetidine, nizatidine or famotidine; and (b) from about 0.250 to about 1.0 Gm of an alkali metal or alkaline-earth metal salts of citric acid or mixtures of such salts.
8. The tablet of claim 7 wherein the citric acid salt is chosen from sodium, potassium, magnesium or calcium salts or mixtures thereof.
9. The tablet of claim 7 wherein the citric acid salt is trisodium citrate.
10. The tablet of claim 7 which additionally com-prises a carbonate or bicarbonate.
11. A tablet, comprising:
(a) an effective amount of an analgesic chosen from the group consisting of Aspirin*, acetaminophen, ibuprofen and ketoprofen; and (b) from about 0.250 to about 1.0 Gm of an alkali metal or alkaline-earth metal salts of citric acid or mixtures of such salts.
(a) an effective amount of an analgesic chosen from the group consisting of Aspirin*, acetaminophen, ibuprofen and ketoprofen; and (b) from about 0.250 to about 1.0 Gm of an alkali metal or alkaline-earth metal salts of citric acid or mixtures of such salts.
12. The tablet of claim 11 wherein the citric acid salt is chosen from sodium, potassium, magnesium or calcium salts or mixtures thereof.
13. The tablet of claim 11 wherein the citric acid salt is trisodium citrate.
14. The tablet of claim 11 which additionally com-prises a carbonate or bicarbonate.
15. A tablet, comprising:
(a) an effective amount of a sympathomimetic amine drugs chosen from the group consisting of phenylpropanolamine, phenylephrine and pseudoephridine; and (b) from about 0.250 to about 1.0 Gm of an alkali metal or alkaline-earth metal salts of citric acid or mixtures of such salts.
(a) an effective amount of a sympathomimetic amine drugs chosen from the group consisting of phenylpropanolamine, phenylephrine and pseudoephridine; and (b) from about 0.250 to about 1.0 Gm of an alkali metal or alkaline-earth metal salts of citric acid or mixtures of such salts.
16. The tablet of claim 15 wherein the citric acid salt is chosen from sodium, potassium, magnesium or calcium salts or mixtures thereof.
17. The tablet of claim 15 wherein the citric acid salt is trisodium citrate.
18. The tablet of claim 15 which additionally com-prises a carbonate or bicarbonate.
19. A method of preparing a granulate of a sodium salt of an acidic therapeutic drug of limited water solubility for use in dosage forms which require high water solubility, comprising the steps of:
(a) mixing an acidic therapeutic drug of limited water solubility with anhydrous trisodium citrate to form a dry mixture;
(b) adding a near saturated aqueous solution of trisodium citrate to the dry mixture to form an overwet granulation mixture;
(c) mixing the overwet mixture for a time sufficient to allow the anhydrous trisodium citrate to hydrate, forming a mixture dry enough to granulate; and (d) granulating the hydrated mixture.
(a) mixing an acidic therapeutic drug of limited water solubility with anhydrous trisodium citrate to form a dry mixture;
(b) adding a near saturated aqueous solution of trisodium citrate to the dry mixture to form an overwet granulation mixture;
(c) mixing the overwet mixture for a time sufficient to allow the anhydrous trisodium citrate to hydrate, forming a mixture dry enough to granulate; and (d) granulating the hydrated mixture.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67616591A | 1991-03-27 | 1991-03-27 | |
| US676,165 | 1991-03-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2061520A1 CA2061520A1 (en) | 1992-09-28 |
| CA2061520C true CA2061520C (en) | 2003-04-22 |
Family
ID=24713495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002061520A Expired - Fee Related CA2061520C (en) | 1991-03-27 | 1992-02-19 | Delivery system for enhanced onset and increased potency |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5424075A (en) |
| EP (1) | EP0505872A1 (en) |
| JP (1) | JPH05112445A (en) |
| KR (1) | KR100238550B1 (en) |
| AU (1) | AU636810B2 (en) |
| CA (1) | CA2061520C (en) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2061520C (en) * | 1991-03-27 | 2003-04-22 | Lawrence J. Daher | Delivery system for enhanced onset and increased potency |
| US5922351A (en) * | 1991-03-27 | 1999-07-13 | Bayer Corporation | Lubricants for use in tabletting |
| DE4341310A1 (en) * | 1993-12-03 | 1995-06-08 | Hexal Pharma Gmbh | Tablet or capsule containing stable ranitidine hydrochloride Form 1 |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| US6348216B1 (en) * | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
| US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| TW482675B (en) * | 1997-01-31 | 2002-04-11 | Green Cross Corp | Compositions for oral administration containing pyridazinone compounds technical field of the invention |
| US5728401A (en) * | 1997-04-16 | 1998-03-17 | Ranbaxy Laboratories, Ltd. | Effervescent ranitidine formulations |
| NZ333474A (en) | 1998-01-02 | 1999-06-29 | Mcneil Ppc Inc | A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat |
| US6197347B1 (en) | 1998-06-29 | 2001-03-06 | Andrx Pharmaceuticals, Inc. | Oral dosage for the controlled release of analgesic |
| US8231899B2 (en) * | 1998-09-10 | 2012-07-31 | Nycomed Danmark Aps | Quick release pharmaceutical compositions of drug substances |
| EP1109534B1 (en) * | 1998-09-10 | 2003-02-12 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
| AU783656B2 (en) | 1999-09-02 | 2005-11-24 | Nostrum Pharmaceuticals, Inc. | Controlled release oral dosage suitable for oral administration |
| US6264984B1 (en) | 1999-12-06 | 2001-07-24 | Bristol-Myers Squibb Company | Effervescent histamine H2 antagonist composition |
| SK285706B6 (en) * | 1999-12-09 | 2007-06-07 | Reckitt Benckiser Healthcare (Uk) Limited | Compressed tablet composition, method for its preparation and use thereof |
| AU2002232492A1 (en) * | 2000-12-06 | 2002-06-18 | Pharmacia Corporation | Rapidly dispersing pharmaceutical composition comprising effervescent agents |
| GB0114069D0 (en) * | 2001-06-08 | 2001-08-01 | Smithkline Beecham Plc | Composition |
| JP2005508325A (en) | 2001-09-28 | 2005-03-31 | マクニール−ピーピーシー・インコーポレイテッド | Dosage form having an inner core and an outer shell |
| US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
| US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
| US7122143B2 (en) | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
| CH693586A8 (en) * | 2002-10-14 | 2003-12-15 | Roche Consumer Health Ag | Formulation of ibuprofen sodium. |
| ITMI20022619A1 (en) * | 2002-12-11 | 2004-06-12 | Ind Italiana Integratori Trei S P A | PHARMACEUTICAL PREPARATIONS FOR VETERINARY USE CONTAINING ACETYLSALICYLIC ACID IN THE FORM OF SOLUBLE BUFFERED POWDER. |
| US20040176234A1 (en) * | 2003-03-07 | 2004-09-09 | Baker Hughes Incorporated | Method for improving separation operation of centrifuges and associated improved separation designs |
| US20040186180A1 (en) * | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
| CA2519772C (en) | 2003-03-21 | 2016-05-31 | Mcneil-Ppc, Inc. | Use of acetaminophen for providing a sustained therapeutic effect |
| US20080020042A1 (en) * | 2003-10-14 | 2008-01-24 | Peter Gruber | Dosage form of sodium ibuprofen |
| US20050095300A1 (en) * | 2003-10-30 | 2005-05-05 | Wynn David W. | Controlled release analgesic suspensions |
| US20050095299A1 (en) * | 2003-10-30 | 2005-05-05 | Wynn David W. | Controlled release analgesic suspensions |
| US8067029B2 (en) | 2004-01-13 | 2011-11-29 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
| US7879354B2 (en) | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| JP2008500288A (en) * | 2004-05-28 | 2008-01-10 | イメイジノット ピーティーワイ エルティーディー | Oral therapeutic compound delivery system |
| US20050281876A1 (en) | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
| US20060198856A1 (en) * | 2005-03-01 | 2006-09-07 | Keith Whitehead | Ibuprofen suspension stabilized with docusate sodium |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| WO2006115770A2 (en) * | 2005-04-22 | 2006-11-02 | Teva Pharmaceuticals Usa, Inc. | Orally disintegrating pharmaceutical tablet formulations of olanzapine |
| EP3263117A1 (en) * | 2005-11-28 | 2018-01-03 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| GB2443793B (en) * | 2006-04-05 | 2010-12-01 | Reckitt Benckiser Healthcare | Product, method of manufacture and use |
| BRPI0713054A2 (en) * | 2006-06-30 | 2012-04-17 | Mcneil Ppc Inc | solid capsules filled with ibuprofen-containing liquid |
| JP2010510320A (en) | 2006-11-21 | 2010-04-02 | マクニール−ピーピーシー・インコーポレーテツド | Modified release analgesic suspension |
| US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
| US8137694B2 (en) | 2007-08-15 | 2012-03-20 | Mcneil-Ppc, Inc. | Immediate release and sustained release ibuprofen dosing regimen |
| ES2357209B1 (en) * | 2009-05-26 | 2011-12-07 | Fundacion Universitaria San Pablo-Ceu | FAMOTIDINE-BASED SOLID PHARMACEUTICAL COMPOSITION AGAINST GASTRIC HYPERSECRETION AND OTHER RELATED DISEASES, WITH HIGHER SYNERGIC EFFECTIVENESS AND FASTER PERFORMANCE. |
| BRPI1010748A2 (en) * | 2009-06-22 | 2016-03-22 | Wyeth Llc | ibuprofen sodium tablets and methods for producing pharmaceutical compositions including sodium ibupofrene. |
| AU2013217564B2 (en) | 2012-02-07 | 2017-04-06 | Johnson & Johnson Consumer Inc. | Rapidly disintegrating coated tablets |
| EP2897584A1 (en) | 2012-09-18 | 2015-07-29 | McNeil-PPC, Inc. | Low melting propionic acid derivative particles for use in oral dosage forms |
| CN104640571A (en) | 2012-09-18 | 2015-05-20 | 麦克内尔-Ppc股份有限公司 | Sustained release oral dosage forms comprising low melting propionic acid derivative particles |
| CA3031474A1 (en) | 2016-07-19 | 2018-01-25 | Johnson & Johnson Consumer Inc. | Tablets having discontinuous coated regions |
| US10583089B2 (en) | 2016-07-19 | 2020-03-10 | Johnson & Johnson Consumer Inc. | Tablets having discontinuous coated regions |
| AU2019208501A1 (en) | 2018-01-22 | 2020-07-02 | Johnson & Johnson Consumer Inc. | Perforated capsules |
| US20210378968A1 (en) | 2020-05-28 | 2021-12-09 | Johnson & Johnson Consumer Inc. | Multi-cavity customizable dosage forms |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB882567A (en) * | 1959-05-30 | 1961-11-15 | Smith & Nephew | Improvements in or relating to the stabilization of dichloralphenazone |
| FR1374388A (en) * | 1963-06-26 | 1964-10-09 | Stamicarbon | Process for the preparation of acetic acid by catalytic oxidation of propylene |
| US3803304A (en) * | 1965-07-19 | 1974-04-09 | Armour Pharma | Orally administratable pancreatic enzymes and methods of using same |
| FR4924M (en) * | 1965-12-01 | 1967-03-20 | ||
| GB1291281A (en) * | 1969-03-20 | 1972-10-04 | Pfizer Ltd | Improvements in pharmaceutical compositions |
| US3865935A (en) * | 1972-08-10 | 1975-02-11 | Abbott Lab | Tableting of erythromycin base |
| JPS5695113A (en) * | 1979-12-28 | 1981-08-01 | Ajinomoto Co Inc | Antibiotic pharmaceutical for oral administration |
| CA1239349A (en) * | 1983-10-10 | 1988-07-19 | Eberhard F. Gottwald | Pharmaceutical composition containing cimetidine |
| NL8400911A (en) * | 1984-03-22 | 1985-10-16 | Dagra Nv | PROCESS FOR PREPARING A PHARMACEUTICAL FORM OF ADMINISTRATION CONTAINING TETRACYCLINE OR DOXYCYCLINE SALTS. |
| GB8600397D0 (en) * | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
| FR2593065B1 (en) * | 1986-01-22 | 1988-09-09 | Smith Kline French Lab | EFFERVESCENT COUPLES, EFFERVESCENT COMPOSITIONS OF HISTAMINE H2 ANTAGONISTS CONTAINING THEM AND THEIR PREPARATION. |
| YU120988A (en) * | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
| JP2525478B2 (en) * | 1989-03-01 | 1996-08-21 | 帝人株式会社 | Active Vitamin D with improved stability (3) Lower solid preparation |
| CA2009326C (en) * | 1989-05-09 | 1998-01-27 | Lawrence J. Daher | Aqueous granulation solution and a method of tablet granulation |
| GB8920693D0 (en) * | 1989-09-13 | 1989-10-25 | Nicholas Kiwi Pty Ltd | Non-effervescent ibuprofen compositions |
| JPH03112928A (en) * | 1989-09-25 | 1991-05-14 | Otsuka Pharmaceut Co Ltd | Pharmaceutical composition improved in absorbability |
| US5064656A (en) * | 1989-11-14 | 1991-11-12 | Dr. Gergely & Co. | Uncoated pharmaceutical reaction tablet |
| CA2039742A1 (en) * | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
| AU7981391A (en) * | 1990-06-22 | 1992-01-23 | Beecham Group Plc | Novel treatment |
| CA2061520C (en) * | 1991-03-27 | 2003-04-22 | Lawrence J. Daher | Delivery system for enhanced onset and increased potency |
| JPH09255A (en) * | 1995-04-20 | 1997-01-07 | Daiwa Kasei Kk | Variant type thermolysin yt73 and its gene |
-
1992
- 1992-02-19 CA CA002061520A patent/CA2061520C/en not_active Expired - Fee Related
- 1992-03-16 EP EP92104479A patent/EP0505872A1/en not_active Ceased
- 1992-03-23 JP JP4094863A patent/JPH05112445A/en active Pending
- 1992-03-25 AU AU13179/92A patent/AU636810B2/en not_active Ceased
- 1992-03-26 KR KR1019920004886A patent/KR100238550B1/en not_active IP Right Cessation
- 1992-06-29 US US07/908,527 patent/US5424075A/en not_active Expired - Lifetime
-
1995
- 1995-03-06 US US08/398,722 patent/US5656293A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU636810B2 (en) | 1993-05-06 |
| US5656293A (en) | 1997-08-12 |
| KR100238550B1 (en) | 2000-02-01 |
| AU1317992A (en) | 1992-10-15 |
| KR920017641A (en) | 1992-10-21 |
| EP0505872A1 (en) | 1992-09-30 |
| US5424075A (en) | 1995-06-13 |
| JPH05112445A (en) | 1993-05-07 |
| CA2061520A1 (en) | 1992-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2061520C (en) | Delivery system for enhanced onset and increased potency | |
| FI77371C (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN KAPSEL, SOM INNEHAOLLER ETT ALKALISKT AEMNE OCH ACETYLSALICYLSYRA. | |
| US5348745A (en) | Aqueous granulation solution and a method of tablet granulation | |
| US6077536A (en) | Pharmaceutical formulation | |
| IE61692B1 (en) | Pharmaceutical compositions | |
| US4294819A (en) | Alkaline analgesic capsule | |
| MXPA06011860A (en) | Pharmaceutical compositions comprising an amphiphilic starch. | |
| IE59135B1 (en) | Effervescent composition containing ibuprofen | |
| EP1007006B1 (en) | Cefadroxil monohydrate tablet formulation | |
| US10258562B2 (en) | Effervescent tablet containing high level of aspirin | |
| EP0396972B2 (en) | An aqueous granulation solution and a method of tablet granulation | |
| WO1991015197A1 (en) | Pharmaceutical formulation | |
| JP2004533461A (en) | Swallow tablets containing paracetamol | |
| WO2002058666A2 (en) | Process for preparing non-hygroscopic sodium valproate composition | |
| US4153678A (en) | Levamisole effervescent tablets | |
| US6274172B1 (en) | Therapeutic effervescent compositions | |
| CA1165242A (en) | Compressed and formed alkaline component suitable for use in buffered acetylsalicylic acid product | |
| JP2000063269A (en) | Solid preparation | |
| US3676549A (en) | Administration of alkali metal salts of salicylamide | |
| EP0836472B1 (en) | Therapeutic effervescent compositions | |
| JPS6049603B2 (en) | Magnesium-containing drugs | |
| EP3675832A1 (en) | Fast self dispersible dosage forms of deferasirox | |
| JP2002128670A (en) | Medicinal composition for tablet | |
| NZ243613A (en) | Tablet comprising praziquantel, pyrantel pamoate and oxantel pamoate in synergistic proportions for treatment of nematode infestations | |
| AU2002241960A1 (en) | Process for preparing non-hygroscopic sodium valproate composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed | ||
| MKLA | Lapsed |
Effective date: 20070219 |